PSP Research’s BioMarin Pharmaceuticals BMRN Stock Holding History

PSP Research’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,772	Closed	-$521K	–	85
2025 Q4	$521K	Buy	+8,772	New	+$478K	0.46%	64

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PSP Research's BMRN Position: Q1 2026 in Review

PSP Research sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 8,772 shares — an estimated $521K sold.

PSP Research first reported a position in BMRN in Q4 2025 and held it in 1 quarter. The position peaked at $521K in Q4 2025. 559 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

PSP Research reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
PSP Research sold 8,772 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $521K.
PSP Research first reported a position in BioMarin Pharmaceuticals in Q4 2025 and held it in 1 quarter.
PSP Research's BioMarin Pharmaceuticals position peaked at $521K in Q4 2025.
559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on PSP Research's 13F filing for Q1 2026, filed 17 Apr 2026.